Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

(2015) Stuart McPherson et al.   JOURNAL OF HEPATOLOGY

Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical Markers

(2014) Wah-Kheong Chan et al.   PLoS One

A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver

(2013) Raluca Pais et al.   JOURNAL OF HEPATOLOGY

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease

(2013) Kenneth Cusi et al.   JOURNAL OF HEPATOLOGY

Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers

(2012) J. Shen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

(2012) Naga Chalasani et al.   GASTROENTEROLOGY

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008

(2011) Zobair M. Younossi et al.   Clinical Gastroenterology and Hepatology

A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients

(2010) R. Anty et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

(2010) Christopher D. Williams et al.   GASTROENTEROLOGY

Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection

(2010) Brad Q. Starley et al.   HEPATOLOGY

Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease

(2009) Y. YILMAZ   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study

(2009) Ariel E. Feldstein et al.   HEPATOLOGY

A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)

(2008) Zobair M. Younossi et al.   OBESITY SURGERY